SCHEMBL4024630

SCHEMBL4024630

c1ccc(COc2ccccc2OCCN2CCOCC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 2/20 0.71
DRD4 P21917 2/20 0.71
DRD5 P21918 2/20 0.71
ALDH1A1 P00352 2/20 0.62
LTA4H P09960 2/20 0.62
POLB P06746 2/20 0.60
KDM4E B2RXH2 4/20 0.59
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
MCHR1 Q99705 1/20 0.56
HTT P42858 1/20 0.56
KMT2A Q03164 1/20 0.56
TDP1 Q9NUW8 1/20 0.53
SIGMAR1 Q99720 1/20 0.53
HRH1 P35367 1/20 0.52
DRD3 P35462 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19068983 0.88 MCHR1 (0.63) DRD1DRD4DRD5ALDH1A1LTA4H
SCHEMBL1956688 0.85 LTA4H (0.79) DRD1DRD4DRD5LTA4HKDM4E
SCHEMBL14578233 0.84 DRD1 (0.65) DRD1DRD4DRD5LTA4HPOLB
SCHEMBL9274541 0.82 DRD1 (0.63) DRD1DRD4DRD5LTA4HPOLB
SCHEMBL5319656 0.82 KDM4E (0.70) DRD1DRD4DRD5ALDH1A1POLB
SCHEMBL13096987 0.82 MCHR1 (0.68) DRD1DRD4DRD5ALDH1A1LTA4H
SCHEMBL21886975 0.81 LTA4H (0.65) DRD1DRD4DRD5ALDH1A1LTA4H
SCHEMBL14925325 0.81 MCHR1 (0.61) DRD1DRD4DRD5ALDH1A1LTA4H
Ammonia Solution, Strong SCHEMBL4267670 0.81 KDM4E (0.68) DRD1DRD4DRD5ALDH1A1POLB
SCHEMBL8703127 0.80 DRD1 (0.74) DRD1DRD4DRD5LTA4HPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450348-B2 Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects FORMA TM, LLC (US) 2013-05-28 US disclosed
EP-2096107-A1 Derivatives of squaric acid with anti-proliferative activity GPC Biotech AG (DE) 2009-09-02 EP disclosed
EP-1674457-B1 Derivatives of squaric acid with anti-proliferative activity GPC BIOTECH AG (DE) 2009-06-03 EP disclosed
US-20080200523-A1 Derivatives of squaric acid with anti-proliferative activity Valo Health, LLC 2008-08-21 US disclosed
EP-1674457-A1 Derivatives of squaric acid with anti-proliferative activity GPC Biotech AG (DE) 2006-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200523-A1 Derivatives of squaric acid with anti-proliferative activity SQLE, FDFT1, DLD DRD1 2362/4885DRD4 3529/4885DRD5 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.